CompletedPhase 2NCT02129075
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
Studying Malignant melanoma of the mucosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Nina BhardwajCancer Immunotherapy Trials Network
- Intervention
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401(biological)
- Enrollment
- 60 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2018
Study locations (7)
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
- Mount Sinai Hospital, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Cleveland Clinic Foundation, Cleveland, Ohio, United States
- Providence Portland Medical Center, Portland, Oregon, United States
- University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02129075 on ClinicalTrials.govOther trials for Malignant melanoma of the mucosa
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06797297A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic TherapyInnovent Biologics (Suzhou) Co. Ltd.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05661955A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.BeiGene
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05089370Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal MelanomaUniversity of Colorado, Denver
- RECRUITINGPHASE2NCT04879654Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic SurgeryEye & ENT Hospital of Fudan University